173 related articles for article (PubMed ID: 37388747)
21. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
22. Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer.
Qiu X; Qu Y; Guo B; Zheng H; Meng F; Zhong Z
J Control Release; 2022 Jan; 341():498-510. PubMed ID: 34883139
[TBL] [Abstract][Full Text] [Related]
23. PKHB1, a thrombospondin-1 peptide mimic, induces anti-tumor effect through immunogenic cell death induction in breast cancer cells.
Calvillo-Rodríguez KM; Mendoza-Reveles R; Gómez-Morales L; Uscanga-Palomeque AC; Karoyan P; Martínez-Torres AC; Rodríguez-Padilla C
Oncoimmunology; 2022; 11(1):2054305. PubMed ID: 35402082
[TBL] [Abstract][Full Text] [Related]
24. Effector memory cytotoxic CD3
Sun X; Zhai J; Sun B; Parra ER; Jiang M; Ma W; Wang J; Kang AM; Kannan K; Pandurengan R; Zhang S; Solis LM; Haymaker CL; Raso MG; Mendoza Perez J; Sahin AA; Wistuba II; Yam C; Litton JK; Yang F
Mod Pathol; 2022 May; 35(5):601-608. PubMed ID: 34839351
[TBL] [Abstract][Full Text] [Related]
25. CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer.
Oshi M; Asaoka M; Tokumaru Y; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32971948
[TBL] [Abstract][Full Text] [Related]
26. Cancer cell-derived exosomal miR-20a-5p inhibits CD8
Li W; Han G; Li F; Bu P; Hao Y; Huang L; Bai X
Cancer Sci; 2024 Feb; 115(2):347-356. PubMed ID: 38129137
[TBL] [Abstract][Full Text] [Related]
27. circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape.
Dong LF; Chen FF; Fan YF; Zhang K; Chen HH
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349124
[TBL] [Abstract][Full Text] [Related]
28. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
29. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
30. An immunogenic cell death-related classification predicts response to immunotherapy and prognosis in triple-negative breast cancer.
Cheng XY; Liang Y; Zhang HF; Qian FZ; Sun XH; Liu XA
Am J Transl Res; 2023; 15(4):2598-2609. PubMed ID: 37193173
[TBL] [Abstract][Full Text] [Related]
31. Ketoglutaric acid can reprogram the immunophenotype of triple-negative breast cancer after radiotherapy and improve the therapeutic effect of anti-PD-L1.
Tan H; Liu J; Huang J; Li Y; Xie Q; Dong Y; Mi Z; Ma X; Rong P
J Transl Med; 2023 Jul; 21(1):462. PubMed ID: 37438720
[TBL] [Abstract][Full Text] [Related]
32. Molecular characterization of immunogenic cell death indicates prognosis and tumor microenvironment infiltration in osteosarcoma.
Liu Z; Liu B; Feng C; Li C; Wang H; Zhang H; Liu P; Li Z; He S; Tu C
Front Immunol; 2022; 13():1071636. PubMed ID: 36569869
[TBL] [Abstract][Full Text] [Related]
33. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas.
Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y
Front Immunol; 2023; 14():1102094. PubMed ID: 37153540
[TBL] [Abstract][Full Text] [Related]
34. Eribulin promotes proliferation of CD8
Shimizu T; Oba T; Oshi M; Ito KI
Breast Cancer Res Treat; 2024 Jan; 203(1):57-71. PubMed ID: 37733186
[TBL] [Abstract][Full Text] [Related]
35. A Dual-Targeting Liposome Enhances Triple-Negative Breast Cancer Chemoimmunotherapy through Inducing Immunogenic Cell Death and Inhibiting STAT3 Activation.
Luo K; Yang L; Yan C; Zhao Y; Li Q; Liu X; Xie L; Sun Q; Li X
Small; 2023 Oct; 19(40):e2302834. PubMed ID: 37264710
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
37. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
38. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral Plasmid IL12 Expands CD8
Telli ML; Nagata H; Wapnir I; Acharya CR; Zablotsky K; Fox BA; Bifulco CB; Jensen SM; Ballesteros-Merino C; Le MH; Pierce RH; Browning E; Hermiz R; Svenson L; Bannavong D; Jaffe K; Sell J; Foerter KM; Canton DA; Twitty CG; Osada T; Lyerly HK; Crosby EJ
Clin Cancer Res; 2021 May; 27(9):2481-2493. PubMed ID: 33593880
[TBL] [Abstract][Full Text] [Related]
40. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
Yang Z; Sun JK; Lee MM; Chan MK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
